Summary Contingent value rights (CVRs) — conditional payments tied to regulatory approval, reimbursement milestones, or sales thresholds — have become standard practice in pharma and biotech acquisitions, with their use
Bristol Myers Squibb and Hengrui Pharma announced a wide-ranging strategic agreement on May 12, 2026, covering 13 drug programs across oncology, hematology, and immunology. BMS commits $950 million at signing
Summary Eli Lilly and Gilead Sciences have each completed multiple acquisitions since the start of 2026, making this one of the most active years for pharma M&A since at least
Summary UCB, a Belgian pharmaceutical company, has announced a $2.2 billion deal to acquire Candid Therapeutics, a startup focused on developing bispecific antibodies for autoimmune diseases. This acquisition adds to
Chiesi Acquires KalVista: A Major Move in the Rare Disease Market Summary Chiesi Group, a family-owned Italian drugmaker, has announced plans to acquire KalVista Pharmaceuticals for $1.9 billion in order
Teva’s Strategic Move: Acquiring Emalex for Potential Tourette Syndrome Treatment Access impact Teva Pharmaceutical, known for its generic drugs, is making a strategic move to expand its portfolio with the
Summary Merck & Co. recently acquired Terns Pharmaceuticals for $6.7 billion, saving almost $1 billion due to updated data on their leukemia drug TERN-701. Merck’s research team believes that this
Summary Boehringer Ingelheim announced successful results from a Phase 3 trial for their obesity shot, survodutide. The therapy showed significant weight loss compared to a placebo, with a potential benefit
Executive Summary New Phase 3 data have been published for lonvo-z. As a result, MARA has placed the asset under structured surveillance reassessment. The current MARA Rating for lonvo-z remains
Lilly to Acquire Ajax Therapeutics in Pursuit of Improved JAK Inhibitor Summary Lilly announced on Monday that it will acquire biotech startup Ajax Therapeutics for up to $2.3 billion. The